Frontline Pertuzumab for Metastatic Breast Cancer

First-Line Treatment of HER2-Positive Metastatic Breast CancerПодробнее

Frontline T-DM1 in HER2-Positive Metastatic Breast CancerПодробнее

CLEOPATRA Trial: Pertuzumab Regimen for Frontline HER2-Positive Metastatic Breast CancerПодробнее

Current Treatment Options for Patients With HER2-Positive Metastatic Breast CancerПодробнее

Dr. Osborne on Pertuzumab in HER2+ Breast CancerПодробнее

Stories of Hope: Facing Breast Cancer (Full Show)Подробнее

The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast CancerПодробнее

Frontline Therapy in Metastatic Breast CancerПодробнее

Paclitaxel With Pertuzumab Plus Trastuzumab in Metastatic Breast CancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BCПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

Current and future HER2+, HR- metastatic breast cancer treatment approachesПодробнее

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast CancerПодробнее

DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancerПодробнее

Treatment strategies for HER2+ metastatic breast cancerПодробнее

PRECIOUS: pertuzumab retreatment in patients with HER+ breast cancerПодробнее

Trastuzumab (Herceptin) and Pertuzumab (Perjeta) for Breast Cancer: What You Need to KnowПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее